Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Sunday, 12 / 16 / 2018

Articles

Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review

REVIEW ARTICLE

Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review

Mattia Bellan*,1,2,3, Luigi Mario Castello1,4 and Mario Pirisi1,5

1Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy
2Division of Internal Medicine, “Sant’Andrea Hospital”, Vercelli, Italy
3IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy
4Emergency Medicine Department, “AOU Maggiore della Carità”, Novara, Italy
5Division of Internal Medicine, “AOU Maggiore della Carità, Novara, Italy

*Correspondence to: Mattia Bellan, Department of Translational Medicine, Università del Piemonte Orientale UPO, via Solaroli 17, Novara (NO) 28100, Italy. Tel: +39-321-3733966, Fax: +39-321-3733361, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2018;6(3):317-325 DOI: 10.14218/JCTH.2018.00006
Received: January 24, 2018 Accepted: May 3, 2018 Published online: July 2, 2018

Abstract

Repair of sustained liver injury results in fibrosis (i.e. the accumulation of extracellular matrix proteins), and ultimately the complete distortion of parenchymal architecture of the liver, which we call cirrhosis. Detecting and staging of fibrosis is thus a mainstay in the management of chronic liver diseases, since many clinically relevant decisions, such as starting treatment and/or monitoring for complications including hepatocellular carcinoma, may depend on it. The gold standard for fibrosis staging is liver biopsy, the role of which, however, is questioned nowadays because of cost, hazards and poor acceptance by patients. On the other hand, imaging techniques and/or measurement of direct and indirect serum markers have not proved to be completely satisfactory under all circumstances as alternatives to liver biopsy. Making progress in this field is now more crucial than ever, since treatments for established fibrosis appear on the horizon. Fine dissection of the pathways involved in the pathophysiology of liver diseases has put forward several novel candidate biomarkers of liver fibrosis, such as growth arrest-specific6, Mac-2-binding protein, osteopontin, placental growth factor, growth/differentiation factor 15 and hepatocyte growth factor. All molecules have been suggested to have potential to complement or substitute methods currently used to stage liver diseases. Here, we review the pros and cons for their use in this setting.

Keywords

Liver fibrosis, Staging, Biomarkers, Gas6, HGF, PlGF

 

 

 

Journal of Clinical and Translational Hepatology 2018 vol. 6, 317-325  [ Html ] [ PDF Full-text ]

 

© The Authors 2018. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 

 logo

You are here: Home